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Abstract
In this study, we investigated the time course gene
expression profile of preneoplastic nodules and
hepatocellular carcinomas (HCC) to define the genes
implicated in cancer progression in a resistant hepato-
cyte model. Tissues that included early nodules
(1 month, ENT-1), persistent nodules (5 months,
ENT-5), dissected HCC (12 months), and normal livers
(NL) from adult rats were analyzed by cDNA arrays in-
cluding 1185 rat genes. Differential genes were derived
in each type of sample (n = 3) by statistical analysis.
The relationship between samples was described in
a Venn diagram for 290 genes. From these, 72 genes
were shared between tissues with nodules and HCC. In
addition, 35 genes with statistical significance only in
HCC and with extreme ratios were identified. Differential
expression of 11 genes was confirmed by comparative
reverse transcription–polymerase chain reaction,
whereas that of 2 genes was confirmed by immunohis-
tochemistry. Members involved in cytochrome P450
and second-phase metabolism were downregulated,
whereas genes involved in glutathione metabolism
were upregulated, implicating a possible role of gluta-
thione and oxidative regulation. We provide a gene ex-
pression profile related to the progression of nodules
into HCC, which contributes to the understanding of
liver cancer development and offers the prospect for
chemoprevention strategies or early treatment of HCC.
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Introduction
Hepatocellular carcinoma (HCC) is a cancer that is prevalent
worldwide. Detection of serum a-fetoprotein and liver imag-
ing techniques are the conventional methods used for the
identification of this malignancy [1–3]. However, these tech-
niques are not reliable for early diagnosis [4]. Early detection
of HCC is an important issue because effective treatment of
small tumors is possible by surgical resection [5]. The early
stages of human and animal hepatocarcinogenesis are char-
acterized by the presence of preneoplastic lesions, namely,
nodules that could be useful for the identification of early
tumor markers, for the study of liver cancer progression, and
for chemopreventive strategies [6,7]. However, human pre-
cancerous lesions such as dysplasic nodules are rather difficult
to obtain because of their small size, incidental detection, and
coexistence with other liver pathologies [8]. Thus, the rat model
for hepatocarcinogenesis has been proven important as a
tool for the analysis of nodules and liver cancer progression.
Chemically induced nodules in the rat liver share several mor-
phologic, biochemical, and molecular characteristics with
human dysplasic nodules [9]. In the resistant hepatocyte (RH)
model described by Solt and Farber [10] and Farber and Sarma
[11], a necrogenic dose of diethylnitrosamine (DEN) induces
resistant hepatocytes (RHs) during initiation. These cells can be
stimulated to develop rapidly into altered hepatocyte foci and
nodules by a selection procedure in which the carcinogen 2-
acetylaminofluorene (2-AAF) is administered in combination
with partial hepatectomy (PH) [12,13]. With this regime, which
induces rapid growth of resistant altered hepatocytes, visible
nodules are formed synchronously—some of them displaying
sufficient genomic damage and progress to HCC without any
additional treatment with the carcinogen.
As with other cancers, HCC is caused by the accumulation
of genetic alterations resulting in a distorted expression of
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thousands of genes. Hence, gene expression analysis with
DNA microarray methodologies has been successfully used
to study cancer development [14,15]. In this study, using a
modified RH model, we investigated the time course of ex-
pression changes during the progression of nodules toward
cancer using Atlas array membranes bearing 1185 well-
typified rat genes. By comparing the expression data be-
tween tissues with nodules andHCC, wewere able to provide
a list of selectively expressed genes at different stages and
those genes shared in both situations. We showed that some
of the differentially regulated genes are involved in glutathi-
one metabolism and redox control, agreeing with the propo-
sition that altered cellular homeostasismay be a predisposing
factor for disease progression in rat hepatocarcinogenesis.
Materials and Methods
Animals and Treatments
F344 rats weighing 180–200 g (UPEAL-Cinvestav, Mex-
ico, DF, Mexico) were subjected to a 10-day carcinogen
treatment. All experiments followed Institutional Animal Care
and Use Committee Guidelines. Rats were initiated with an
intraperitoneal dose of DEN (200 mg/kg; Sigma–Aldrich,
Toluca, Mexico) and subjected to a modified selection re-
gime 1 week later [6,16]. 2-AFF was administered by ga-
vage at a dose of 25 mg/kg during three consecutive days,
beginning on day 7 after initiation. On day 10, rats were
subjected to PH. Animals were sacrificed by exsanguination
under ether anesthesia at periods from 1month after initiation
up to 24 months. Livers were excised, washed in physio-
logical saline solution, frozen in 2-methyl butane with liquid
nitrogen or immersed in RNAlater (Sigma, St. Louis, MO),
and stored at 80jC.
Histologic Analyses
Representative 20-mm thick sections from liver slices
were stained for g-glutamyl transpeptidase (GGT) activity,
in accordance with Rutenburg et al. [17]. In addition, 5-mm
sections were processed for routine histologic examination
using hematoxylin and eosin (H&E) staining. For immuno-
staining, formalin-fixed paraffin specimens were blocked for
1 hour in 0.1% H2O2 in phosphate-buffered saline, pH 7.4.
Subsequently, they were incubated with commercial mono-
clonal antibodies specific to glutathione S-transferase, pla-
cental form (GSTP; DakoCytomation, Glostrup, Denmark),
or anti–cyclin D1 (Cell-Marque, Hotspring, AR) diluted 1:50
and 1:20, respectively, in blocking buffer overnight. After
washing with phosphate-buffered saline, the primary anti-
body was detected using an avidin–biotin complex immuno-
peroxidase technique (Zymed Laboratories, Inc., Carlsbad,
CA). No staining was observed when the primary antibody
was substituted with mouse isotype control.
Liver Section, Enrichment of Nodular Tissue,
and Tumor Dissection
Hepatocellular tumors with diameters larger than 5 mm
were easily dissected, and their corresponding nontumorous
(Nt) liver tissues were obtained. Small nodular lesions 0.5 to
3 mm in diameter were distinguished by their sharp grayish
white color demarcation from the surrounding reddish brown
liver. Then a stainless steel cork borer (internal diameter,
1 mm) was introduced into frozen tissues. In this way, be-
tween 15 and 25 nodules per liver were collected, pooled,
and stored in RNAlater at 80jC. These samples were
designated as enriched nodular tissues (ENTs). The in-
creased presence of the hepatocarcinogenesis markers
GSTP and GGT in ENT was verified by comparative reverse
transcription–polymerase chain reaction (RT-PCR).
RNA Isolation, cDNA Synthesis, Labeling, and Purification
The total RNA of normal livers (NL), ENT of 1 month
(ENT-1), ENT of 5 months (ENT-5), and individual HCC
samples were obtained by tissue homogenization and ex-
traction with Trizol (Life Technologies, Inc.). After DNase
treatment, RNA was purified by phenol chloroform extrac-
tion. RNA quality and concentration were determined by
capillary electrophoresis (RNA Nano LabChip; Agilent Tech-
nologies, Massy, France). For cDNA synthesis, 20 mg of RNA
was reverse-transcribed for 1.5 hours at 42jC with 200 U
of Superscript II reverse transcriptase (Invitrogen, Carlsbad,
CA); 6 ml of 5 first strand buffer (Invitrogen); 1 mg of
oligo(dT15); 50 mCi of [a-
33P]dCTP (2500 Ci/mmol; Amer-
shamBiosciences, Pittsburgh, PA); 5 mMdCTP; 0.8mMeach
of dATP, dGTP, and dTTP; and 10 mM dithiothreitol, in a final
volume of 30 ml. After 1 hour, 200 U of Superscript II reverse
transcriptase was added to the reaction mixture. The result-
ing 33P-labeled cDNA was purified with MicroSpin S-200 HR
columns (Amersham Biosciences), according to the manu-
facturer’s instructions.
cDNA Microarray Membrane and Hybridization
Atlas rat toxicology cDNA expression 1.2 arrays (7860-1)
were purchased from Clontech Laboratories, Inc. (Palto Alto,
CA) The membranes contained 1176 known rat genes and 9
housekeeping control cDNA. The arrays were prehybridized
with 15 ml of Church buffer [18] and 0.5 mg of denatured
salmon testes DNA at 65jC for 2 hours, with continuous
agitation. Then, 33P-labeled cDNA was added to the hybrid-
ization buffer at 65jC overnight. The membranes were
washed at 65jC with 40 mM sodium phosphate buffer (pH
7.2) and 0.1% sodium dodecyl sulfate.
Imaging and Analysis
The membranes were then exposed to low-energy phos-
phorimage screens for 2 days. Images were acquired with a
PhosphorImager 445 SI (Molecular Dynamics/Amersham
Biosciences, Pittsburgh, PA). The spots were detected with
XDotsReader (v. 1.8), and data were analyzed with the web
service BioPlot (http://biopuce.insa-toulouse.fr/; Genopole-
Toulouse, Toulouse, France). The intensity of each spot was
corrected by subtracting the background; for normalization,
the intensity of each spot was divided by the mean intensity
of the nine housekeeping genes. From the RNA of rat livers
(NL = 3; ENT-1 = 3; ENT-5 = 3; HCC = 3), 12 independent
sets of data were obtained. Ratio was obtained from the
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average intensity (n = 3) of each gene compared with NL.
Statistical data, such as P values from Student’s t test and
false discovery rate (FDR), were obtained with the BioPlot
system. Genes with statistical significance (P V .05 accord-
ing to Student’s t test) were considered differential genes
and were classified as downregulated (< 1) or upregulated
(> 1) genes according to the ratio. They were grouped and
classified with the web service BioClust (http://biopuce.insa-
toulouse.fr/). Two hundred ninety differential genes detected
in this study through their statistical values are listed in
Table W1. The level of similarity of gene expression patterns
was obtained by hierarchical clustering analysis, as deter-
mined by Euclidean distance and a complete linkage method
using the web-available software Hierarchical Clustering
Explorer (http://www.cs.umd.edu/hcil/hce/).
Comparative RT-PCR
RT-PCR was performed by a modification of the compar-
ative PCR method [19]. Both cDNA synthesis and PCR were
performed in one step (One Step RT-PCR System; Gibco
Invitrogen Corp., Carlsbad, CA). Appropriate primers (0.2 mM
each) and 1 mg of total RNA per 50 ml of reaction were used.
The absence of DNA contamination was verified by PCR
assay. Cycling parameters were as follows: 30 minutes at
45jC for cDNA synthesis, followed by 1 minute at 94jC;
annealing for 45 seconds between 52jC and 60jC, followed
by 1 minute at 72jC; and final elongation for 10 minutes at
72jC. An adequate number of cycles corresponding to
exponential amplification was performed to avoid saturated
products with a kinetic analysis of 20–35 cycles for each
gene. Primer set sequences are shown in Table 1.
Results
Progression Stage in the Modified RH Model
Hepatocyte nodules and tumor lesions were identified
by determination of the marker GGT and by H&E staining
(Figure 1). The amount of liver lesions expressing posi-
tive GGT activity during the progression stage is shown in
Table 2. Numerous nodules up to 2 mm in diameter were
uniformly stained for GGT activity at 1 month (Figure 1A).
They contained clear eosinophilic cytoplasmic hepatocytes
with minimal nuclear atypia (Figure 1B). The number of
nodules showed a significant decrease from 1 to 5 months
(Table 2), which is associated with the presence of remodel-
ing and persistent nodules, as described by Enomoto and
Farber [20]. Persistent nodules were detected mainly at
5 months, and they showed the largest areas (up to 3 mm2)
with a uniform presence ofGGTactivity (Figure 1C). They had
cytologic features similar to those of early nodules, but the
increased size of the lesion compressed the surrounding
NL (Figure 1D). HCC were found after 7 months, and with
higher incidence at 12 months (Table 2). These lesions with
variable histologic GGT activity had areas greater than
5 mm2 (Figure 1E ). HCC exhibited increased thickness of
the layers of hepatocytes, marked nucleoli, mitotic figures,
nuclear atypia, and anisonucleosis (Figure 1F ).
Identification of Genes with Differential Expression
in Hepatocellular Lesions
To investigate genes related to the progress of nodules
toward HCC, the gene expression profiles of liver lesions
samples (n = 3) were compared to NL profiles. The number of
differential genes between ENT-1/NL, ENT-5/NL, and HCC/
NL was 143, 172, and 156, respectively, corresponding to
290 genes. Venn diagram (Figure 2) was used to classify the
290 genes whose expression change was specific to or
common in the comparisons. The complete data, including
Venn diagram sections, gene names, functional classifica-
tions, ratios, and FDRs, are shown in Table W1. According to
the main functions of the differential genes in Table W2, the
highest proportion of selected genes was related to cellular
metabolism (80 genes), followed by cell receptors and intra-
cellular transducer genes (31 and 30 genes, respectively).
Differential genes with intersections between ENT and
HCC were considered important because they could reflect
the continuous process from preneoplasia to neoplasia. From
Table 1. Primer Pairs Used for RT-PCR in This Study.
Gene Name Short Name GenBank
Accession
Number
Forward and Reverse Primers (5V–3V) Product
Size (bp)
Glutathione S-transferase pi 1 GSTP1 X02904 TGCCACCGTACACCATTGTGT; CAGCAGGTCCAGCAAGTTGTA 479
Glutamate–cysteine ligase,
catalytic subunit
GCLC J05181 GCTGCATCGCCATTTTACCGAG; TGGCAACAGTCATTAGTTCTCCA 883
Glutamate cysteine ligase,
modifier subunit
GCLM L22191 AGCTGGACTCTGTCATCATGG; TGGGTCATTGTGAGTCAGTAGC 290
Glutathione synthetase GSS L38615 CACTATCTCTGCCAGCTTTGG; GTTCCTTTCCTTCTCCTGAGC 211
Annexin 5 ANXA5 M21730 ATGGCTCTCAGAGGCACCGT; CGTGTTTCAGCTCGTAGGCG 289
Glutathione reductase GSR U73174 CCATGTGGTTACTGCACTTCC; TTCTGGAACTCGTCCACTAGG 171
g-Glutamyl transpeptidase GGT1 M33821 CTCTGCATCTGGCTACCCAC; GGATGCTGGGTTGGAAGAGG 418
Cytochrome P450, subfamily
IIC (CYP2C11)
CYP2C11 J02657 TCATTCCCAAGGGTACCAATG; GGAACAGATGACTCTGAATTCT 664
Sulfotransferase,
estrogen-preferring
STE M86758 CTGGAGAGAGACCCATCAGC; TCATTTGCTGCTGGTAGTGC 223
Betaine–homocysteine
methyltransferase
BHMT AF038870 GTCATGCAGACCTTCACTTTCTA; TAAGGCCTCGACTGCCCACACG 315
Regucalcin RGN D38467 AGATGAACAAATCCCAGAT; ACCCTGCATAGGAATATGG 305
a-Actin a-ACTIN X80130 CCAAGGCCAACCGCGAGAAGATGAC; AGGGTACATGGTGGTGCCGCCAGAC 584
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the intersection of genes among the three comparisons,
72 genes shared between ENT and HCC were selected;
40 of these showed statistical significance in the three lesion
development stages. These genes are displayed in Figure 3
according to ratio; their classification by hierarchical cluster-
ing indicates the different patterns of gene expression from
early nodules to HCC. Analysis of clustered data revealed
at least five behaviors in gene expression patterns. There
are upregulated genes in clusters 1 and 2; the first cluster
includes upregulated genes with a high ratio in three lesion
development stages, such as the known hepatocarcino-
genesis marker GST pi with ratios of ENT-1/NL = 13.59,
ENT-5/NL = 21.89, and HCC/NL = 22.76, whereas upregu-
lated genes in cluster 2 showed a high ratio in two lesion
development stages (e.g., glutamate–cysteine ligase modi-
fier; ENT-1/NL= 1.26, ENT-5/NL= 2.42, and HCC/NL= 4.59).
Cluster 3 includes genes with transitions from upregulated
levels in ENT to downregulated levels in HCC (e.g., metal-
lothionein; ENT-1/NL= 5.08, ENT-5/NL= 2.29, andHCC/NL=
0.55). Cluster 4 includes genes with transitions from down-
regulated levels in ENT-1 to upregulated levels in HCC (e.g.,
cyclin D1; ENT-1/NL = 0.34, ENT-5/NL = 0.41, and HCC/NL =
2). Cluster 5 contains downregulated genes in three lesion
development stages (e.g., CYP450-2C11; ENT-1/NL = 0.37,
ENT-5/NL = 0.34, and HCC/NL = 0.14).
To extend the selection of important differential genes in
hepatocarcinogenesis, from the 84 genes that showed sta-
tistical significance only inHCC, the highly upregulated genes
(ratio z 2) and the highly downregulated genes (ratio V 0.5)
were selected; the expression level of these 35 genes in the
three lesion development stages is shown in Figure 4.
Clustering analysis resulted in four gene clusters: cluster 1,
highly upregulated genes in HCC with a tendency for up-
regulation in ENT (e.g., Annexin 5; ENT-1/NL = 1.39, ENT-5/
NL = 1.43, and HCC/NL = 3.63); cluster 2, highly upregulated
Figure 1. Progression of hepatocyte nodules toward HCC in the modified RH model. Histologic determination of GGT activity in early nodules (arrows) of 1 month
(A), intermediate persistent nodule (arrow) of 5 months (C), and HCC (arrow) of 12 months (E). The increased cytologic alterations and distorted hepatocyte
rearrangement in the liver were visualized by H&E staining in an early nodule (B), in a persistent nodule (arrows indicate the borderline of a nodule) (D), and in HCC
(F). Bars in (A), (C), and (E) correspond to 2 mm, whereas bars in (B), (D), and (F) correspond to 50 m.
Table 2. Quantitative Histologic Analysis of GGT-Positive Hepatocellular
Lesions in Rats.
Sacrifice
(months)
Nodules/cm2
(Mean ± SD)
Persistent
Nodules (%)*
Rats with
HCC
1 22.31 ± 3.74 1.85 ± 1.7 0/7
3 15.25 ± 1.80 3.89 ± 2.6 0/3
5 4.71y ± 1.77 14.61y ± 7.2 0/6
7 16.06 ± 7.34 1.99 ± 3.4 2/4
12 6/6
*Uniformly stained nodules with area > 1 mm2.
yStatistically different compared with the 1-month group.
Figure 2. Differentially expressed genes in liver lesions against NL. Venn
diagram of 290 differential genes. Considering NL as reference, the
differential genes were determined by statistical significance ( P V .05,
Student’s t test) in ENT-1, ENT-5, and HCC samples (n = 3 for each sample).
From the intersection (*), 72 genes that were shared by ENT-1, ENT-5, and
HCC are listed in Figure 3. From the 84 differential genes in HCC/NL, 19
highly downregulated (ratio V 0.5) and 16 highly upregulated (ratio z 2)
genes are listed in Figure 4.
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Figure 3. Gene expression patterns of 72 genes shared by ENT and HCC. As indicated in Figure 2, the genes from intersections 12*, 40*, and 20* were compiled.
The labels of intersection in the Venn diagram, gene names, GenBank accession numbers, and main functions are shown. The genes were classified by
hierarchical clustering, and the ratio average of each type of sample (columns) is presented in a matrix format. Green and red represent downregulation and
upregulation, respectively, as indicated in the scale bar (log2 ratio – transformed scale). The dendrogram in blue or red on the left indicates the degree of similarity of
selected genes. The clusters indicate the different behaviors of genes in the three types of sample.
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genes in HCC with a tendency for downregulation in ENT
(e.g., protein kinase inhibitor a; ENT-1/NL= 0.72, ENT-5/NL=
0.94, and HCC/NL = 2.08); cluster 3, highly downregulated
genes in HCC with a tendency for upregulation in ENT [e.g.,
betaine–homocysteinemethyltransferase (BHMT); ENT-1/NL
= 1.19, ENT-5/NL = 0.75, and HCC/NL = 0.28]; and, cluster 4,
highly downregulated genes in HCC with a tendency for
downregulation in ENT (e.g., cytochrome P450 IIA1; ENT-1/
NL = 0.83, ENT-5/NL = 0.39, and HCC/NL = 0.34).
Immunohistologic Analysis of GSTP and Cyclin D1 in HCC
From the upregulated genes in HCC (Figure 3), the high-
est ratio (HCC/NL = 23) was found for theGSTP gene, which
is the most important marker in rat hepatocarcinogenesis
models; at the limits, the gene that is considered highly
upregulated (HCC/NL = 2) is cyclin D1, which is an important
oncogene involved in cell cycle regulation. To confirm the
upregulation of these genes at the protein level, immuno-
histochemistry was performed in histologic serial sections of
HCC (Figure 5). A specific increased level of GSTP in the
cytoplasm of HCC cells was evident when compared to ad-
jacent tissues (Figure 5A). In the same way, cyclin D1 was
significantly increased in the nucleus of neoplastic hepato-
cytes (Figure 5B). These genes illustrate that upregulation
for some genes at the mRNA level induces increased pro-
tein levels.
Comparative RT-PCR Confirming Differential Gene
Expression of Selected Genes
To validate cDNA array results, we used comparative RT-
PCR for gene expression analysis. From the genes listed in
Figures 3 and 4, four downregulated and seven upregulated
selected genes (Table 1) were compared with mRNA levels
in NL, ENT-1, ENT-5, HCC, and in the corresponding Nt
tissues of two rats sacrificed at 15 months (Figure 6). There
was a notable correspondence in the ratios obtained from
cDNA arrays and the band level determined by RT-PCR. The
11 genes analyzed were consistent with their respective
downregulation or upregulation in ENTand HCC with respect
to NL. Because the surrounding Nt tissue is an important
reference for histologic demarcation of tumor and marker
discovery, we compared mRNA levels between these two
samples. It is significant to note that there were higher levels
of upregulated genes in tumors than in Nt tissues, and vice
versa in downregulated genes. Thus, besides the validation
of the altered expression of these genes, they could be
Figure 4. Gene expression patterns of highly upregulated or downregulated genes in HCC. As indicated in Figure 2, genes with an expression ratio that had at least
a two-fold difference were selected from the 84 genes that showed a statistical difference (P V .05) only in the HCC/NL comparison. The genes were classified by
hierarchical clustering as in Figure 3.
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important for the histologic distinction of tumors from adja-
cent Nt tissues.
Discussion
Animal models of hepatocarcinogenesis recapitulate the
underlying biology of liver tumorigenesis and have provided
reliable data for understanding the cellular development
of HCC in humans [21–23]. The progression stage in the
RH model is characterized by the evolution from nodules to
HCC without additional carcinogen treatment. The majority
of nodules remodel or differentiate into a liver of normal ap-
pearance, whereas a few persistent nodules show spon-
taneous cell proliferation and size increase [20,24–26].
Considering that all rats with hepatic nodular lesions will
present with HCC after 9 to 10 months [11], it is possible to
hypothesize that nodular cells may have an altered genetic
background that allows them to accumulate additional muta-
tions and, after a selection process, to show autonomous cell
proliferation. These genetic alterations should predispose
nodules to undergoing a slow evolution to cancer; however,
this issue remains unclear.
One positive feature of this model is its ability to distin-
guish a few persistent nodules from a large number of
remodeling nodules and, thus, to allow a study of the
nodule’s cancer sequence [11]. According to our histologic
analysis, the highest proportion of persistent nodules with-
out HCC occurrence was found at 5 months. Although they
were few in the liver, the increase in size of up to 3 mm in
diameter allowed us to collect them easily from the frozen
liver. Thus, we performed the study at three periods of prog-
ression: initial point, with tissues that included early nodules
(1 month); intermediate point, with tissues that included
persistent nodules (5 months); and end point, with well-
developed HCC (12 months).
The evaluation of array results against NL, together with
statistical analysis, allowed us to reveal differential gene
expression patterns within each progression condition and
to compare them. The known hepatocarcinogenesis markers
such as a2-macroglobulin [27], GGT, and GSTP were up-
regulated, showing congruence of cDNA array results. With
equal coherence, the oncogene cyclin D1 showed a two-fold
increased mRNA level in array results and an increased
protein presence in GSTP-positive cancer cells. Further-
more, differential gene expression was validated for 11 genes
by comparative RT-PCR (four downregulated genes and
seven upregulated genes). It is important to note that the
expression of these genes was also compared in tumorous
and corresponding adjacent Nt tissues of two rats sacrificed
15 months after DEN treatment, showing that tumorous
tissues can be molecularly differentiable from surrounding
tissues. The differential mRNA levels of the indicated genes
in tumor and nontumor tissues could be useful for the
development of additional tools for the histopathological
evaluation and confirmation of HCC. There is a need for a
noninvasive method for early HCC diagnosis; for this reason,
we will perform additional studies focusing on gene products
such as the secreted protein Annexin 5, which will lead to the
identification of serological markers.
It is known that hepatocyte nodules are precursors for
HCC [26]. With this in mind, we selected the genes that were
statistically significant from preneoplasia to neoplasia; these
Figure 5. Histologic confirmation of increased GSTP and cyclin D1 levels in HCC. Immunoperoxidase staining of GSTP (A) and cyclin D1 (B) in serial sections of
HCC of a rat sacrificed 15 months after initiation. Scale bars, 200 m.
Figure 6. Confirmation of the differential expression of 11 genes by RT-PCR.
Comparison of mRNA levels of 11 selected genes plus a-actin as control in
NL, ENT-1, and ENT-5; individual tumors (T) at 12 and 17 months; and pairs
of tumors (T) and corresponding Nt tissues at 15 months. Only for RT-PCR
were RNA samples of NL and ENT pooled from three livers. Full gene names
are shown in Table 1.
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72 genes showed a wide pattern of expression courses from
tissues with early nodules to liver cancer. Those genes with
consistent upregulation (i.e., GCL, glutamate–cysteine li-
gase, and others) or with consistent downregulation (i.e.,
sulfotransferase, estrogen-preferring; CYP2C11; and
others) from early nodules to HCC may form a fraction of
an altered gene expression environment that predisposes
nodules to progressing into HCC, and they would be consid-
ered as underlying genes involved in the progression stage
of hepatocarcinogenesis. It was not surprising that, among
these genes,GSTP was found because it is widely used as a
marker in the basic analysis of chemical carcinogenesis
[28,29]. Furthermore, other GST gene family members
(i.e., a and m) were upregulated with a similar course of ex-
pression, indicating perhaps the same transcriptional regu-
lation or response to inducers [30].
The systems of transforming growth factor a and hepa-
tocyte growth factor (HGF), and their receptors epidermal
growth factor receptor (EGFR) and met proto-oncogene,
respectively, are mitogenic for hepatocytes and have been
suggested to contribute to HCC formation [31,32]. In our
results, the four genes showed downregulated levels from
early nodules to HCC, with ratios between 0.34 and 0.67
(Table W1). Our data are in agreement with previous reports
that showed no increased presence of these gene products
in rat preneoplastic and neoplastic hepatocytes [31,33,34].
In human HCC, expression of HGF and EGFR has shown
great variability with respect to the pattern of histologic
differentiation of HCC [35,36]. However, other growth factors
showed upregulation in at least one lesion development
stage, as follows (ENT-1, ENT-5, and HCC): fibroblast growth
factor 10—4.09, 4.24, and 1.37; insulin-like growth factor 1—
2.53, 1.3, and 0.48; insulin-like growth factor binding protein 1
(Igfbp1)—2.46, 2.5, and 1.1; and Igfbp3—0.4, 0.6, and 2.07
(Table W1). The results from these growth factor studies
have stimulated us to undertake additional investigations
to understand the preferential cell proliferation of preneo-
plastic and neoplastic lesions.
There is strong evidence for the involvement of oxidative
stress in hepatocarcinogenesis. Oxidative stress may trigger
damage to cellular membranes and nuclear DNA, which
result in lipid peroxidation and oxidative DNA damage, re-
spectively. Here, by statistical selection, we have detected
several differential genes involved in the control and regula-
tion of oxidative stress: upregulated genes such as those for
NAD(P)H dehydrogenase quinone 1, superoxide dismutase
2, mitochondrial alcohol dehydrogenase 1, peroxiredoxin,
and thioredoxin reductase 1; downregulated genes such as
those for carbonic anhydrase 3 and glutathione peroxidase;
and genes with a transition from upregulated levels in pre-
neoplasia to downregulated levels in cancer, such as that
for metallothionein. The specific increase at the protein
level of metallothionein in rat liver preneoplastic lesion has
been demonstrated by Sawaki et al. [37], whereas down-
regulated expression in hepatocellular tumors has been
described for human and mouse chemical carcinogenesis
[38]. Although the participation of metallothionein in cell
proliferation and carcinogenesis has been suggested [39],
additional analysis should be performed to examine the
possible correlation between its expression and preneo-
plastic/neoplastic transition.
Many reports indicate that reduced glutathione (GSH) and
its cooperating enzymes are important in neoplastic dis-
eases and play a crucial role in defense against reactive
oxygen species [40,41]. In rat chemical hepatocarcino-
genesis models, increased levels of GSH, oxidized gluta-
thione, GGT, and GSTP are often detected in preneoplastic
hepatocyte nodules and hepatocellular tumors [42,43]. In our
transcriptome analysis, we detected more than 10 genes that
are involved in GSH metabolism. Figure 7 maps the modu-
lation of some differential genes atmRNA levels in HCC in the
metabolic pathways of GSH biosynthesis, amino acid recy-
cling, antioxidation in GSH, and redox control for DNA
synthesis. The upregulation of the GCLC, GCLM, and GSH
synthetases essential for GSH biosynthesis could explain
the increased levels of total glutathione in hepatocarcino-
genesis. Moreover, the upregulation of GGT, glycine trans-
porter 1 (Slc6a9), and solute carrier family 17-vesicular
glutamate transporter member 1 (Slc17a1) could favor the
catabolism of extracellular GSH and the recovery of glycine
and glutamate, respectively. The downregulation of the liver
multidrug resistance–associated protein 6 gene (Abcc6),
which acts as a MgATP-dependent efflux pump that trans-
ports glutathione S-conjugates [44], could maintain the in-
creased level of intracellular glutathione. One of the major
determinants of the rate of GSH synthesis is the availability
of cysteine [45]; N-acetyltransferase-2 catalyzes the N-
acetylation of the cysteine conjugate (X-Cys), resulting in
the formation ofmercapturic acid, which is usually excreted in
urine (its downregulated expression in hepatocellular tumors
could be an adaptive response to maintaining the amount
of cysteine essential for GSH biosynthesis). Another impor-
tant source of cysteine comes from the trans-sulfuration
pathway, which converts methionine to cysteine. Methionine
can be resynthesized from homocysteine through the activ-
ity of BHMT; this gene was downregulated in tumors, favoring
the idea that maintaining cysteine for GSH biosynthesis is
an adaptive response of neoplastic cells.
GST gene products and GSH peroxidase 1 (Gpx1) share
the ability to reduce organic peroxides through GSH oxida-
tion. Nevertheless, contrary to GST genes, the Gpx1 gene
was downregulated from early nodules to HCC, indicating
that liver cancer may develop in a Gpx1-deficient condition.
Reduced expression of this gene was reported in rat experi-
mental HCC [46], and reduced activity was reported in
human HCC [47,48]. The reduction of this important scav-
enger enzyme of toxic oxygen radicals exemplifies a shared
phenomenon in HCC development in humans and rats.
Several reports and our data suggest that the altered gene
expression of oxidative stress–related genes and GSH me-
tabolism genes plays an important role in predisposing nod-
ular hepatocytes to progression toward HCC. GSH level
increases in human HCC and hepatocytes during active
proliferation with respect to NL [45,49]. An increased level
of GSH has been detected in a number of drug-resistant
tumor cell lines and in tumor cells isolated from patients
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whose tumors are clinically resistant to drug therapy [50]. In
human HCC, increased hepatic oxidative DNA damage has
been reported on patients with HCC [51,52]. However, in the
future, it will be important to determine the chronological
causative participation of oxidative stress and GSH regula-
tion in human and rat hepatocarcinogeneses.
Gene expression profiles provide a guide for the under-
standing of HCC development. Hierarchical clustering clas-
sification also allowed us to conclude that the pattern of gene
expression is more similar between nodular samples at 1
and 5 months relative to HCC. A similar concept was found
histologically in H&E staining (Figure 1), in which the cyto-
logic features of early and persistent nodular hepatocytes
are modestly altered with respect to neoplastic cells in
cancer. Thus, gene profiles exemplify the continuous pro-
gression from nodules to HCC.
Numerous researchers have used microarrays to profile
the gene expression pattern of human HCC, and they have
found thousands of altered genes [15,22,27,53]. However,
among these genes, it is difficult to discern which are critical
for HCC development and are not just a consequence of
increased genomic instability. It is known that liver cancer, as
with other solid malignancies, displays a high number of
genetic alterations and huge heterogeneity in gene expres-
Figure 7. Mapping of some differentiable genes in cellular metabolic pathways. (A) Glutathione (GSH) biosynthesis and amino acid recycling. (B) Antioxidant
function of GSH. (C) Role of GSH and NADPH in DNA synthesis and cytochrome oxidation. (z) Upregulated differential genes (red). (#) Downregulated differential
genes (green). BHMT, betaine–homocysteine methyltransferase; GGT, c-glutamyl transpeptidase; GCL, glutamate cysteine ligase; GST, glutathione S-
transferase; Abcc6, liver multidrug resistance-associated protein 6.
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sion profiles. For this reason, it is essential to differentiate the
important genes implicated in liver tumorigenesis with re-
spect to those genes that are not related to cancer develop-
ment or are considered as biologic noise.
The gene expression patterns associated with human
HCC progression have been addressed by a comparison
of early HCC and nodule-in-nodule-type HCC (advanced
HCC within early HCC) [53]. Heat shock protein 70
(HSP70) was identified as a marker of early HCC. Coinci-
dentally, we found increased levels of the HSP70-8 in ENT-1
(ratio = 2.79), ENT-5 (ratio = 2.99), and HCC (ratio = 1.51)
(Table W1). Lee et al. [22] have revealed two subclasses
of HCC patients, characterized by the expression profiles
of a limited number of genes that accurately predict the
length of survival. Some of these genes with downregulated
levels [such as regucalcin (RGN), insulin receptor (Insr),
interleukin 6 receptor (Il6r), enoyl coenzyme A hydratase
short chain 1 (Echs1), androgen receptor (Ar), and acyl co-
enzyme A oxidase 2 branched chain (Acox2)] were also
downregulated in rat HCC (Table W1), whereas upregulated
genes [such as tyrosine 3-monooxygenase/tryptophan
5-monooxygenase activation protein eta polypeptide
(Ywhah); serine (or cysteine) proteinase inhibitor clade H,
member 1 (Serpinh1); ribosomal proteins S3, S5, and S9
(Rps3,Rps5, andRps9); nucleophosmin 1 (Npm1); fatty acid
binding protein 5 epidermal (Fabp5); and cold shock domain
protein A (Csda)] were increased in both human and rat
HCC. The potential of the RH model, together with DNA
microarray technology, has allowed us to reveal gene ex-
pression changes in rat HCC that could be relevant to
human HCC.
To increase the screening of global gene expression
during hepatocarcinogenesis, we are now expanding our
study to high-density oligonucleotide microarrays. In the
present work studying 1185 rat genes, it was possible to
identify a gene expression profile that is related to the
progression of rat hepatocarcinogenesis, which suggests
altered cellular homeostasis as a predisposing factor for the
evolution of nodules toward cancer. Furthermore, data may
provide opportunities to find new markers for rat liver pre-
neoplastic nodules and target genes for chemoprevention or
early treatment of HCC.
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Table W1. Statistical Differential Genes, Classified According to the Venn’s Diagram (Figure 2).
Venn Gene Name Symbol Genbank Functional Ratio FDR
Section Classification
ENT1/NL ENT5/L HCC/NL
12 fatty acid binding protein 7 Fabp7 U02096 trafficking/targeting proteins 0.39* 0.71 0.4* 0.00040
12 liver multidrug resistance-associated
protein 6
Abcc6 U73038 stress response proteins 0.68* 0.61 0.42* 0.00050
12 inter alpha-trypsin inhibitor,
heavy chain 4
ltih4 Y11283 protein turnover 2.68* 1.35 0.43*
12 serine (or cysteine) proteinase
inhibitor, clade A, member 1
M32247 protein turnover 0.63* 0.48 0.57* 0.00032
12 Lipase, hepatic Lipc M16235 metabolism 2.71* 2.25 0.73*
12 Rat senescence marker protein
2A gene, exons 1 and 2
Smp2a X63410 metabolism 5.67* 1.44 0.48*
12 Cytochrome P450, subfamily llC6 Cyp2c6 K03501 metabolism 2.08* 1.03 0.35*
12 Cytochrome P450, subfamily IIC
(mephenytoin 4-hydroxylase)
Cyp2c J02657 metabolism 0.37* 0.34 0.14* 0.00049
12 mitogen activated protein kinase 3 Mapk3 M61177 intracellular transducers/
effectors/moduIators
0.46* 0.61 1.48*
12 Complement component 4 binding
protein, alpha
C4bpa Z50051 immune system proteins 1.56* 1.14 0.63*
12 Keratin 8 Krt2-8 M63482 cytoskeleton/motility proteins 0.69* 0.86 1.76*
12 activin beta E lnhbe AF089825 cell signaling, extracellular
communication proteins
1.35* 0.89 0.72*
20 ribosomal protein L6 Rpl6 X87107 translation 1.99 1.96 2.01* 0.00040
20 N-Acetyltransferase-2 Nat2 U17261 stress response proteins 0.61 0.48* 0.53* 0.00047
20 Cathepsin L Ctsl Y00697 protein turnover 1.12 1.33 1.63*
20 angiotensinogen Agt L00091 protein turnover 0.38 0.22* 0.38* 0.00039
20 cyclin D1 Ccnd1 D14014 oncogenes and tumor
suppressors
0.34 0.41* 2*
20 UDP-glucuronosyltransferase Ugt2b4 U06273 metabolism 1.48 1.97* 1.34* 0.00051
20 enolase 1, alpha Eno1 X02610 metabolism 1.43 1.98* 1.28*
20 hypoxanthine guanine phosphoribosyl
transferase
Hprt M63983 metabolism 1.78 2.04* 1.24* 0.00049
20 glutamic-pyruvate transaminase
(alanine aminotransferase)
Gpt1 D10354 metabolism 0.6 0.43* 0.64* 0.00048
20 cytochrome P-450PCN (PNCN
inducible)
Cyp3a1 M10161 metabolism 0.69 0.44* 0.28* 0.00043
20 Aldehyde dehydrogenase family 3,
subfamily A1
Aldh3a1 J03637 metabolism 0.69 4.33* 4.52* 0.00069
20 NAD(P)H dehydrogenase, quinone 1 Nqo1 J02608 metabolism 2.02 3.79* 4.97* 0.00048
20 Sterol carrier protein 2, liver Scp2 M34728 metabolism 0.92 0.71* 0.59*
20 UDP glycosyltransferase 1 family,
polypeptide A7
Ugt1a7 U75903 metabolism 1.74 3.01* 6.1* 0.00051
20 alkaline phosphatase, tissue-
nonspecific
AlpI J03572 metabolism 0.48 0.46* 1.85*
20 3-hydroxy-3-methylglutaryl-Coenzyme
A synthase 2
Hmgcs2 M33648 metabolism 0.38 0.21* 0.66* 0.00040
20 glutamate cysteine ligase, modifier
subunit
Gclm L22191 metabolism 1.26 2.42* 4.59* 0.00040
20 Fatty acid binding protein 1, liver Fabp1 M35991 intracellular transducers/
effectors/moduIators
0.68 0.48* 0.33* 0.00052
20 MHC class I-related protein (MR1) Y13972 immune system proteins 0.7 0.33* 0.52* 0.00041
20 Amiloride binding protein 1 Abp1 X73911 extracellular transport/
carrier proteins
0.54 0.61* 0.56* 0.00032
22 nuclear factor I/A Nfia D78017 transcription 0.57* 0.64 0.93 0.00051
22 alpha thalassemia/mental retardation
syndrome X-linked (RAD54 homolog,
S.cerevisiae)
Atrx D64059 transcription 0.49* 0.56 0.89 0.00040
22 Fos like antigen 2 Fosl2 U18913 transcription 0.45* 0.76 0.79 0.00042
22 Early growth response 1 Egr1 M18416 transcription 0.44* 0.48 0.78 0.00051
22 protein disulfide isomerase-related
protein
Txndc7 X79328 trafficking/targeting proteins 2.05* 2.71 0.85
22 ADP-ribosylation factor 3 Arf3 L12382 trafficking/targeting proteins 0.62* 0.77 1.22
22 ATP-binding cassette, sub-family C
(CFTR/MRP), member 2
Abcc2 L49379 stress response proteins 0.4* 0.66 1.21
22 acidic ribosomal protein P0 Arbp Z29530 RNA processing,
turnover, and transport
2.97* 1.87 1.23 0.00053
22 CDC-like kinase 3 Clk3 X94351 RNA processing,
turnover, and transport
0.46* 0.52 0.76 0.00042
22 stress-induced-phosphoprotein 1
(Hsp70/Hsp90-organizing protein)
Stip1 Y15068 post-translational
modification/protein folding
0.56* 0.71 1.3
22 dihydropyrimidine dehydrogenase Dpyd D85035 metabolism 2.89* 1.9 0.77
22 arachidonic acid epoxygenase Cyp2c23 X55446 metabolism 1.63* 1 0.54
Table W1. (continued)
Venn Gene Name Symbol Genbank Functional Ratio FDR
Section Classification
ENT1/NL ENT5/L HCC/NL
22 cytochrome P450, 1a1 Cyp1a1 X00469 metabolism 2.96* 1.24 0.56
22 sodium channel, voltage-gated,
type 1, beta polypeptide
Scn1b M91808 membrane channels and
transporters
0.38* 0.5 1.13 0.00076
22 ATPase, Ca++ transporting,
cardiac muscle, slow twitch 2
Atp2a2 J04022 membrane channels and
transporters
0.43* 0.58 0.79 0.00045
22 phosphodiesterase 3B Pde3b Z22867 intracellular transducers/
effectors/moduIators
0.49* 0.59 0.73
22 Transferrin Tf D38380 extracellular transport/
carrier proteins
1.6* 1.48 0.9 0.00048
22 insulin-like growth factor 1 Igf1 M15480 cell signaling, extracellular
communication proteins
2.53* 1.3 0.48
22 kinase substrate HASPP28 Pdap1 U41744 cell signaling, extracellular
communication proteins
0.63* 0.77 1.4
22 Follicle stimulating hormone receptor Fshr L02842 cell receptors (by ligands) 0.42* 0.6 1 0.00039
22 transforming growth factor, beta
receptor 3
Tgfbr3 M77809 cell receptors (by ligands) 0.36* 0.63 0.71 0.00044
22 nuclear receptor subfamily 2, group F,
member 6
Nr2f6 AF003926 cell receptors (by activities) 0.63* 0.77 0.86 0.00045
40 ribosomal protein S5 Rps5 X58465 translation 4.27* 4.95* 1.39* 0.00040
40 nuclear factor of kappa light chain
gene enhancer in B-cells inhibitor,
alpha
Nfkbia X63594 transcription 0.48* 0.59* 1.19*
40 Inhibitor of DNA binding 3, dominant
negative helix-loop-helix protein
ld3 D10864 transcription 0.42* 0.39* 1.56*
40 Apolipoprotein E Apoe J02582 trafficking/targeting proteins 0.21* 0.2* 0.8* 0.00040
40 glutathione S-transferase, alpha 1 Gsta5 K01932 stress response proteins 3* 3.82* 2.01* 0.00038
40 Metallothionein Mt1a J00750 stress response proteins 5.08* 2.29* 0.55* 0.00186
40 glutathione-S-transferase,
alpha type2
Gsta2 K01931 stress response proteins 5.29* 7.08* 2.8* 0.00011
40 solute carrier family 21, member 1 Slc21a1 L19031 stress response proteins 0.49* 0.44* 0.28* 0.00042
40 endothelin converting enzyme 1 Ece1 D29683 protein turnover 0.35* 0.4* 0.8* 0.00046
40 Glutathione peroxidase 1 Gpx1 X12367 protein turnover 0.54* 0.41* 0.54* 0.00031
40 glucose regulated protein, 58 kDa Grp58 D63378 protein turnover 0.24* 0.4* 0.85* 0.00040
40 protein disulfide isomerase related
protein (calcium-binding protein,
intestinal-related)
Erp70 M86870 post-translational modification/
protein folding
0.42* 0.62* 0.65* 0.00049
40 Superoxide dismutase 2,
mitochondrial
Sod2 X56600 metabolism 0.4* 0.62* 1.14*
40 fatty acid Coenzyme A ligase, long
chain 2
Acsl1 D90109 metabolism 0.64* 0.43* 0.45* 0.00052
40 glycerol kinase Gyk D16102 metabolism 0.31* 0.34* 0.46* 0.00031
40 glutathione S-transferase, mu
type 3 (Yb3)
Gstm3 J02744 metabolism 3.78* 4.86* 2.48* 0.00018
40 peroxiredoxin 5 Prdx6 Y17295 metabolism 2.35* 2.5* 1.65* 0.00049
40 sulfotransferase, estrogen preferring Ste M86758 metabolism 0.5* 0.53* 0.15* 0.00043
40 alcohol dehydrogenase 1 Adh1 M15327 metabolism 10.66* 11.57* 3.74* 0.00041
40 glutathione S-transferase, pi 1 Gstp1 X02904 metabolism 13.59* 21.89* 22.76* 0.00003
40 glutamate-cysteine ligase, catalytic
subunit
Gclc J05181 metabolism 2.28* 4.05* 7.22* 0.00012
40 aldehyde dehydrogenase family 1,
subfamily A4
Aldh1a4 M23995 metabolism 4.24* 6.76* 4.22* 0.00031
40 phosphoenolpyruvate carboxykinase K03243 metabolism 0.43* 0.22* 0.24* 0.00011
40 carbonic anhydrase 3 Ca3 M22413 metabolism 0.3* 0.19* 0.2* 0.00010
40 acyl-Coenzyme A oxidase 2,
branched chain
Acox2 X95189 metabolism 0.31* 0.29* 0.27* 0.00009
40 Phosphoinositide 3-kinase, regulatory
subunit, polypeptide 1 (p85 alpha)
Pik3r1 D64045 intracellular transducers/
effectors/modulators
0.35* 0.27* 0.65* 0.00040
40 GTP-binding protein (G-alpha-i2) Gnai2 M17528 intracellular transducers/
effectors/modulators
0.44* 0.6* 1.72*
40 guanine nucleotide binding protein,
alpha 12
Gna12 D85760 intracellular transducers/
effectors/modulators
0.33* 0.42* 1.48*
40 cold shock domain protein A Csda U22893 DNA binding and chromatin
proteins
0.57* 0.64* 1.96*
40 leukemia inhibitory factor Lif M32748 cell signaling, extracellular
communication proteins
0.34* 0.23* 0.46* 0.00040
40 hepatocyte growth factor Hgf D90102 cell signaling, extracellular
communication proteins
0.48* 0.54* 0.67* 0.00031
40 interleukin 6 receptor ll6r M58587 cell receptors (by ligands) 0.24* 0.17* 0.37* 0.00040
40 Interleukin 1 receptor, type 1 Il1r1 M95578 cell receptors (by ligands) 0.33* 0.26* 0.5* 0.00020
40 epidermal growth factor receptor Egfr M37394 cell receptors (by ligands) 0.43* 0.43* 0.52* 0.00012
40 Retinoid X receptor alpha Rxra L06482 cell receptors (by ligands) 0.17* 0.21* 0.7* 0.00042
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40 Integrin, beta 1 ltgb1 U12309 cell receptors (by ligands) 2.15* 2.42* 1.29* 0.00042
40 ribosomal protein L24 Rp124 X78443 2.72* 3.12* 1.44* 0.00046
40 cytochrome P450, 8b1, sterol 12
alpha-hydrolase
Cyp8b1 AB018596 0.47 0.26* 0.29* 0.00039
43 rap7a Dap U05334 2.56* 3.81* 2.73* 0.00006
43 probasin Pbsn M27156 0.46* 0.48* 0.58* 0.00012
43 retinoblastoma binding protein 7 Rbbp7 AF090306 transcription 0.58 0.59* 1.19
43 nuclear factor l/X Nfix AB012234 transcription 0.47 0.48* 0.83 0.00042
43 alpha1-antitrypsin promoter binding
protein 2 (ATBP2)
Hivep1 X54250 transcription 0.42 0.47* 0.81 0.00040
43 Retinoblastoma-related gene Rbl2 D55627 transcription 0.44 0.48* 0.77 0.00049
43 heat shock 10 kDa protein 1 Hspe1 X71429 stress response proteins 1.54 1.85* 0.9
43 T-complex 1 Tcp1 D90345 stress response proteins 0.88 1.2* 1.14
43 growth arrest and DNA-damage-
inducible 45 alpha
Gadd45a L32591 stress response proteins 0.42 0.34* 0.8 0.00045
43 Finkel-Biskis-Reilly murine sarcoma
virusubiquitously expressed
Fau X62671 protein turnover 0.49 0.41* 1.2 0.00070
43 Peptidylprolyl isomerase A
(cyclophilin A)
Ppia M19533 post-translational modification/
protein folding
1.56 2.45* 1.16
43 suppression of tumorigenicity 13 (colon
carcinoma) Hsp70-interacting protein
St13 X82021 post-translational modification/
protein folding
1.23 2.02* 1.66 0.00040
43 avian sarcoma virus CT10 (v-crk)
oncogene homolog
Crk D44481 oncogenes and tumor
suppressors
0.38 0.29* 1.07 0.00045
43 Kirsten rat sarcoma viral oncogene
homologue 2 (active)
Kras2 U09793 oncogenes and tumor
suppressors
0.55 0.47* 1.24
43 Superoxide dismutase 1, soluble Sod1 Y00404 metabolism 0.51 0.39* 0.92 0.00040
43 acyl-coenzyme A:cholesterol
acyltransferase
Soat1 D86373 metabolism 0.42 0.36* 0.76 0.00050
40 liver UDP-glucuronosyltransferase,
phenobarbital inducible form
Udpgtr2 M13506 metabolism 0.88 0.3* 0.17 0.00040
40 peroxiredoxin 1 Prdx1 D30035 metabolism 1.67 2.56* 1.55 0.00039
43 mel transforming oncogene (derived
from cell line NK14)- RAB8 homolog
Rab8a M83675 intracellular transducers/
effectors/moduIators
0.49 0.58* 0.99 0.00048
43 Protein phosphatase 2 (formerly 2A),
catalytic subunit, alpha isoform
Ppp2ca X16043 intracellular transducers/
effectors/moduIators
2.1 2.86* 1.05 0.00118
43 mitogen activated protein kinase 1 Mapk1 M64300 intracellular transducers/
effectors/moduIators
0.36 0.4* 1.11 0.00082
43 GTPase Rab14 Rab14 M83680 intracellular transducers/
effectors/moduIators
0.46 0.44* 0.89 0.00039
43 calmodulin 3 Calm3 X13817 intracellular transducers/
effectors/moduIators
2.27 3.82* 1.36 0.00052
43 adrenergic receptor, alpha 2c Adra2c M58316 cell receptors (by ligands) 0.52 0.55* 0.9 0.00043
43 insulin-like growth factor 1 receptor lgf1r L29232 cell receptors (by ligands) 0.5 0.4* 0.92 0.00041
43 nuclear receptor subfamily 1, group H,
member 4
Nr1h4 U18374 cell receptors (by ligands) 0.66 0.52* 0.89
43 G protein-coupled receptor 27;
gustatory receptor 27 (GUST27)
Olr1867 D12820 cell receptors (by ligands) 0.55 0.38* 0.77 0.00046
43 parathyroid hormone receptor Pthr1 L19475 cell receptors (by ligands) 0.52 0.5* 0.71 0.00045
43 defender against cell death 1 Dad1 Y13336 cell receptors (by ligands) 1.16 1.66* 1.15 0.00051
43 galanin receptor 1 GaIr1 U30290 cell receptors (by ligands) 0.71 0.62* 0.77 0.00046
43 leukemia inhibitor factor receptor
alpha-chain
Lifr D86345 cell receptors (by ligands) 0.62 0.39* 0.57 0.00049
43 5-hydroxytryptamine (serotonin)
receptor 2B
Htr2b X66842 cell receptors (by ligands) 0.45 0.48* 0.58 0.00046
43 androgen receptor Ar M20133 cell receptors (by activities) 0.46 0.55* 0.73 0.00045
43 cyclin-dependent kinase inhibitor 1B Cdkn1b D83792 cell cycle 0.45 0.45* 0.85 0.00041
43 small GTP-binding protein rab5 Rab5a AF072935 0.4 0.45* 0.95
43 notch gene homolog 2, (Drosophila) Notch2 M93661 0.65 0.67* 0.95
43 Secreted acidic cystein-rich
glycoprotein (osteonectin)
Sparc Y13714 0.7 0.58* 0.9
43 Sp1 transcription factor Sp1 D12768 0.36 0.44* 0.87 0.00042
43 thioredoxin Txn1 X14878 1.74 2.23* 1.19 0.00045
43 collagen, type Ill, alpha 1 Col3a1 M21354 0.87 0.55* 0.86
43 high mobility group AT-hook 1 Hmga1 X62875 0.52 0.52* 0.78 0.00045
43 profilin Pfn1 X96967 1.44 1.69* 1.32
43 non-muscle myosin alkali light chain S77858 2.41 2.64* 1.28 0.00040
43 CCAAT/enhancer binding protein,
gamma
Cebpg X64403 0.36 0.31* 0.67 0.00041
43 epidermal growth factor Egf U04842 0.82 0.55* 0.68 0.00046
69 ribosomal protein S9 Rps9 X66370 translation 4.72* 4.5* 1.35 0.00039
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69 ribosomal protein S3 Rps3 X51536 translation 4.7* 5.08* 1.28 0.00049
69 nucleophosmin 1 Npm1 J03969 translation 2.09* 2.63* 1.49 0.00045
69 hepatocyte nuclear factor 4, alpha Hnf4a D10554 transcription 0.24* 0.22* 0.81 0.00040
69 zinc finger protein 36 Zfp36 X63369 transcription 0.34* 0.34* 0.8 0.00040
69 presenilin 1 Psen1 D82363 trafficking/targeting proteins 0.29* 0.31* 1.08 0.00046
69 ATP-binding cassette, sub-family B
(MDR/TAP), member 4
Abcb4 L15079 stress response proteins 0.3* 0.29* 0.71 0.00046
69 solute carrier family 22, member 5 Slc22a5 AJ001933 stress response proteins 4.5* 6.32* 0.73
69 heat shock 70kD protein 8 Y00054 stress response proteins 2.79* 2.99* 1.51 0.00040
69 tissue inhibitor of metalloproteinase 2 Timp2 L31884 protein turnover 0.46* 0.48* 0.97 0.00041
69 cathepsin B Ctsb X82396 protein turnover 3.04* 3* 1.07 0.00067
69 polyubiquitin Ubb D16554 protein turnover 0.36* 0.43* 0.95 0.00043
69 ubiquitin conjugating enzyme Ube2b M62388 protein turnover 0.43* 0.42* 0.6 0.00048
69 carboxypeptidase D Cpd U62897 protein turnover 0.58* 0.53* 1.13
69 P450 (cytochrome) oxidoreductase Por M12516 post-translational modification/
protein folding
0.36* 0.27* 1.07 0.00078
69 chaperonin containing TCP1, subunit
3 (gamma)
X74801 post-translational modification/
protein folding
3.41* 4* 0.91 0.00111
69 H-ras proto-oncogene; transforming
protein p21
M13011 oncogenes and tumor
suppressors
0.37* 0.37* 0.96 0.00053
69 cyclin D2 Ccnd2 D16308 oncogenes and tumor
suppressors
0.42* 0.43* 0.94 0.00040
69 phosphoglycerate kinase 1 Pgk1 M31788 metabolism 2.03* 2.14* 1.02
69 cytochrome P450, 4a12 Cyp4a12 M37828 metabolism 2.43* 2.73* 1.1 0.00042
69 cytochrome c oxidase, subunit 4a Cox4i1 X14209 metabolism 0.66* 0.68* 0.98
69 7-dehydrocholesterol reductase Dhcr7 AB016800 metabolism 2.9* 3.49* 1.14 0.00109
69 heme oxygenase 2 Hmox2 J05405 metabolism 0.49* 0.43* 0.86 0.00041
69 dopa/tyrosine sulfotransferase Sult1b1 U38419 metabolism 1.53* 1.6* 0.88
69 biliverdin reductase A Blvra M81681 metabolism 0.38* 0.47* 0.93 0.00049
69 Apolipoprotein A-IV Apoa4 M00002 metabolism 0.18* 0.09* 0.68 0.00041
69 cytosolic acyl-CoA thioesterase 1 Cte1 AB010428 metabolism 0.32* 0.39* 1.27 0.00119
69 transferrin receptor Tfrc M58040 metabolism 1.37* 1.18* 1.27
69 mitochondrial H+-ATP synthase alpha
subunit
Atp5a1 X56133 metabolism 4.06* 3.61* 1.15 0.00043
69 carnitine palmitoyltransferase 1 Cpt1a L07736 metabolism 0.25* 0.34* 0.71 0.00040
69 Glyceraldehyde-3-phosphate
dehydrogenase
Gapd M17701 metabolism 1.93* 2.04* 1.24 0.00051
69 cytochrome c oxidase subunit Vb Cox5b D10952 metabolism 0.2* 0.22* 0.76 0.00040
69 ATP-binding cassette, sub-family B
(MDR/TAP), member 6
Abcb6 AJ003004 membrane channels and
transporters
1.42* 2.19* 0.94
69 inositol 1,4,5-triphosphate
receptor type 1
ltpr1 U38665 membrane channels and
transporters
0.41* 0.38* 0.75 0.00040
69 A-raf Araf1 X06942 intracellular transducers/
effectors/moduIators
0.46* 0.56* 1 0.00052
69 mitogen activated protein kinase
kinase 2
Map2k2 D14592 intracellular transducers/
effectors/moduIators
0.37* 0.42* 1.08 0.00061
69 p38 mitogen activated protein kinase Mapk14 U73142 intracellular transducers/
effectors/moduIators
0.33* 0.38* 1.14 0.00069
69 RAS p21 protein activator 1 Rasa1 L13151 intracellular transducers/
effectors/moduIators
0.42* 0.46* 1.16 0.00046
69 Murine thymoma viral (v-akt)
oncogene homolog 2
Akt2 D30041 intracellular transducers/
effectors/moduIators
0.4* 0.39* 0.82 0.00044
69 mitogen-activated protein kinase 6 Mapk6 M64301 intracellular transducers/
effectors/moduIators
0.47* 0.44* 1.22
69 Insulin receptor substrate 1 Irs1 X58375 intracellular transducers/
effectors/moduIators
0.39* 0.49* 0.76 0.00046
69 insulin-like growth factor binding
protein 1
lgfbp1 M89791 extracellular transport/
carrier proteins
2.46* 2.5* 1.11 0.00059
69 insulin-like growth factor binding
protein 3
lgfbp3 M31837 extracellular transport/carrier
proteins
0.4* 0.61* 2.07
69 8-oxoguanine-DNA-glycosylase Ogg1 AF029690 DNA synthesis,
recombination, and repair
0.48* 0.67* 1.04
69 histone 2A H2a U95113 DNA binding and chromatin
proteins
0.18* 0.23* 1.05 0.00070
69 vimentin Vim X62952 cytoskeleton/motility proteins 0.48* 0.43* 1 0.00039
69 alpha-tubulin Tuba1 V01227 cytoskeleton/motility proteins 1.78* 2.24* 1.06
69 fibroblast growth factor 10 Fgf10 D79215 cell signaling, extracellular
communication proteins
4.09* 4.24* 1.37 0.00079
69 Glucose-dependent insulinotropic
peptide
Gip L08831 cell signaling, extracellular
communication proteins
5.69* 4.04* 1.99 0.00052
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69 vascular endothelial growth factor Vegfa M32167 cell signaling, extracellular
communication proteins
0.34* 0.42* 1.16 0.00065
69 interleukin 4 receptor ll4r X69903 cell receptors (by ligands) 0.26* 0.34* 0.89 0.00040
69 met proto-oncogene Met U65007 cell receptors (by ligands) 0.34* 0.36* 0.66 0.00045
69 insulin receptor lnsr M29014 cell receptors (by ligands) 0.37* 0.42* 0.74 0.00052
69 natriuretic peptide receptor 1 Npr1 M74535 cell receptors (by ligands) 0.36* 0.44* 0.66 0.00052
69 growth hormone receptor Ghr J04811 cell receptors (by ligands) 0.41* 0.35* 0.56 0.00050
69 Low density lipoprotein receptor Ldlr X13722 cell receptors (by ligands) 0.43* 0.42* 0.62 0.00032
69 Peroxisome proliferator activated
receptor alpha
Ppara M88592 cell receptors (by activities) 0.26* 0.38* 0.94 0.00050
69 nuclear receptor subfamily 1,
group D, member 1
Nr1d1 M25804 cell receptors (by activities) 0.24* 0.35* 0.71 0.00045
69 Cyclin D3 Ccnd3 D16309 cell cycle 0.31* 0.31* 0.81 0.00043
69 tenascin U15550 cell adhesion receptors/
proteins
0.55* 0.58* 0.9 0.00046
69 tumor necrosis factor receptor
superfamily, member 1
Tnfrsf1a M63122 apoptosis associated proteins 0.23* 0.23* 1.05 0.00047
69 B cell lymphoma 2 like Bcl2l1 U72350 apoptosis associated proteins 0.3* 0.32* 0.81 0.00040
69 myeloid cell leukemia sequence 1 Mcl1 AF115380 apoptosis associated proteins 0.62* 0.44* 1.14
69 UDP-glucuronosyltransferase 1
family, member 1
Ugt1a1 U20551 0.49* 0.45* 0.88 0.00039
69 cytochrome bc-1 complex core P S74321 1.69* 1.57* 1.13
69 cell growth regulatory with ring finger
domain
Cgrrf1 U66471 0.38* 0.45* 0.78 0.00044
69 K-kininogen, differential splicing leads
to HMW Kngk
Kng_v1 L29428 3.58* 3.49* 1.4 0.00043
69 nuclear factor kappa B subunit p65
(NFkB)
AF079314 0.39* 0.48* 1.24 0.00095
69 metallothionein 3 Mt3 S65838 5.56* 2.52* 0.78 0.00128
69 17-beta hydroxysteroid dehydrogenase
type 2
Hsd17b2 X91234 0.72 0.8 0.5* 0.00052
69 actin, beta Actb V01217 cytoskeleton/motility proteins 0.85 0.72 1.27*
69 aldehyde dehydrogenase family 3,
subfamily A2
Aldh3a2 M73714 metabolism 1.41 0.98 0.63*
84 alpha-2-HS-glycoprotein Ahsg X63446 intracellular transducers/
effectors/moduIators
0.98 0.45 0.43* 0.00045
84 alpha-2-macroglobulin A2m J02635 protein turnover 1.07 0.65 2.46*
84 annexin 1 Anxa1 M19967 metabolism 0.93 2.75 5.02* 0.00053
84 annexin 5 Anxa5 M21730 intracellular transducers/
effectors/moduIators
1.39 1.43 3.63* 0.00039
84 Apolipoprotein A-Il Apoa2 X03468 1.16 0.65 0.32*
84 apurinic/apyrimidinic endonuclease 1 Apex1 D44495 DNA synthesis,
recombination, and repair
0.66 0.66 1.56*
84 aquaporin 8 Aqp8 AF007775 membrane channels and
transporters
1.79 4.14 1.77* 0.00040
84 arginase 1 Arg1 J02720 metabolism 1.3 0.72 0.49*
84 arginosuccinate synthetase 1 Ass M36708 metabolism 0.76 0.47 0.31* 0.00044
84 ATP-binding cassette, sub-family C
(CFTR/MRP), member 3
Abcc3 AB010467 stress response proteins 0.7 0.84 1.52*
84 Benzodiazepin receptor (peripheral) Bzrp M84221 cell receptors (by ligands) 0.89 1.4 1.8*
84 betaine-homocysteine
methyltransferase
Bhmt AF038870 metabolism 1.19 0.75 0.28* 0.00089
84 calnexin Canx L18889 intracellular transducers/
effectors/moduIators
0.9 0.94 0.71*
84 calreticulin CaIr X53363 intracellular transducers/
effectors/moduIators
0.69 0.76 0.77*
84 CD24 antigen Cd24 U49062 cell adhesion receptors/
proteins
1.05 0.93 1.53*
84 cell division cycle 42 homolog
(S. cerevisiae)
Cdc42 M35543 intracellular transducers/
effectors/moduIators
2.39 3.4 1.27* 0.00090
84 C-reactive protein Crp M83176 cell signaling, extracellular
communication proteins
1.38 0.78 0.32* 0.00099
84 crystallin, beta B2 Crybb2 X16072 stress response proteins 0.49 0.65 0.65* 0.00041
84 cytochrome P450 2B1 Cyp2b1 M11251 metabolism 1.17 0.88 0.65*
84 Cytochrome P450 IlA1 (hepatic steroid
hydroxylase llA1) gene
Cyp2a1 J02669 metabolism 0.83 0.39 0.34* 0.00039
84 cytochrome P450, 1a2 Cyp1a2 K02422 metabolism 1.52 0.66 0.22* 0.00088
84 cytochrome P450, 7a1 Cyp7a1 J05460 metabolism 0.97 0.61 0.33* 0.00046
84 cytochrome P450, subfamily 17 Cyp17a1 M21208 metabolism 1.02 0.54 0.54* 0.00040
84 cytochrome P450, subfamily 27b,
polypeptide 1
Cyp27b1 AB001992 metabolism 0.65 0.99 0.63* 0.00040
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84 diazepam binding inhibitor Dbi M14201 1.57 1.28 0.6*
84 Discoidin domain receptor family,
member 1
Ddr1 L26525 cell receptors (by activities) 0.71 0.75 5.03*
84 DNA polymerase beta PoIb J02776 DNA synthesis,
recombination, and repair
0.54 0.74 0.68* 0.00039
84 enoyl Coenzyme A hydratase, short
chain 1
Echs1 X15958 metabolism 1.69 1.42 0.69*
84 eukaryotic translation elongation
factor 2
Eef2 K03502 translation 0.75 0.52 1.29*
84 fatty acid binding protein 5,
epidermal
Fabp5 U13253 metabolism 2.38 1.69 1.93* 0.00046
84 Fibrinogen, gamma polypeptide Fgg J00734 1.46 0.89 0.52*
84 Fibronectin 1 Fn1 X05834 extracellular matrix proteins 0.94 0.78 0.49* 0.00044
84 Flavin-containing monooxygenase 1 Fmo1 M84719 stress response proteins 0.87 0.56 0.52* 0.00040
84 fructose-1,6-bisphosphatase 1 Fbp1 M86240 metabolism 1.39 1.05 0.51*
84 gamma-glutamyl hydrolase Ggh U38379 metabolism 0.75 0.89 1.35*
84 gamma-glutamyl transpeptidase Ggt1 M33821 metabolism 1.06 1.25 3.33* 0.00097
84 gastric inhibitory peptide receptor Gipr L19660 cell receptors (by ligands) 0.82 0.93 0.67*
84 glucose-6-phosphate dehydrogenase G6pdx X07467 metabolism 1.6 2.92 3.42* 0.00050
84 glutamate oxaloacetate transaminase 1 Got1 J04171 metabolism 0.84 0.44 0.29* 0.00040
84 glutathione reductase Gsr U73174 metabolism 0.97 1.57 2.35*
84 glutathione synthetase Gss L38615 metabolism 0.55 0.68 2.62*
84 glycine transporter 1 Slc6a9 M88595 membrane channels and
transporters
0.44 0.69 2.39*
84 guanine nucleotide binding protein,
alpha o
Gnao M17526 intracellular transducers/
effectors/moduIators
0.49 0.42 0.42* 0.00048
84 Huntington disease gene homolog Hdh U18650 trafficking/targeting proteins 1.09 0.53 0.6* 0.00108
84 hydroxy-delta-5-steroid
dehydrogenase, 3 beta- and steroid
delta-isomerase
Hsd3b M67465 metabolism 0.54 0.51 0.36* 0.00040
84 hydroxy-delta-5-steroid
dehydrogenase, 3 beta- and steroid
delta-isomerase 1
Hsd3b1 M38178 metabolism 1.09 1.27 0.49*
84 hydroxysteroid dehydrogenase
17 beta, type 7
Hsd17b7 U44803 intracellular transducers/
effectors/moduIators
1.1 0.91 0.71*
84 Inhibitor of DNA binding 2, dominant
negative helix-loop-helix protein
ld2 D10863 transcription 0.86 0.72 2.24*
84 lactate dehydrogenase B Ldhb U07181 metabolism 0.63 0.92 1.94*
84 laminin receptor 1 (67kD, ribosomal
protein SA)
Lamr1 D25224 2.49 1.74 1.65* 0.00065
84 Male germ cell-associated kinase Mak M35862 intracellular transducers/
effectors/moduIators
0.74 0.85 1.36*
84 mitogen-activated protein kinase 12 Mapk12 X96488 intracellular transducers/
effectors/moduIators
0.65 0.47 0.55* 0.00039
84 mouse double minute 2, human
homolog of; p53-binding protein
Z12020 transcription 0.53 0.65 1.61*
84 neuropilin-2 Nrp2 AF016297 cell receptors (by ligands) 0.75 0.98 1.84*
84 O6-methylguanine-DNA
methyltranferase
Mgmt X54862 DNA synthesis,
recombination, and repair
0.93 1.23 0.76*
84 phospholipase A2, group VI Pla2g6 U51898 metabolism 0.48 0.75 1.62*
84 pre-alpha inhibitor heavy chain 3 ltih3 X83231 protein turnover 1.74 1.42 0.58*
84 Prion protein, structural Prnp D50093 0.94 0.87 1.74*
84 protein kinase inhibitor, alpha Pkia L02615 intracellular transducers/
effectors/moduIators
0.72 0.94 2.08*
84 Protein phosphatase 2 (formerly 2A),
catalytic subunit, beta isoform
Ppp2cb M23591 intracellular transducers/
effectors/moduIators
0.84 1.06 1.99*
84 Regucalcin Rgn D38467 intracellular transducers/
effectors/moduIators
1.36 0.74 0.31* 0.00089
84 ribosomal protein L15 Rpl15 X78167 translation 0.95 0.75 1.32*
84 ribosomal protein L3 Rpl3 X62166 1.25 0.94 1.32*
84 serine (or cysteine) proteinase
inhibitor, clade H, member 1
Serpinh1 M69246 stress response proteins 0.52 0.42 2.14*
84 Serine protease inhibitor Spin2c D00753 protein turnover 1.23 1.18 0.75*
84 serine protease inhibitor 2.4 Serpina3m X69834 protein turnover 1.05 0.92 0.39*
84 signal transducer and activator of
transcription 1
Stat1 AF205604 1.08 1.07 0.64*
84 sodium-dependent neutral amino acid
transporter ASCT2
SIc1a5 AJ132846 membrane channels and
transporters
0.53 0.72 0.61* 0.00043
84 solute carrier family 17 vesicular
glutamate transporter), member 1
Slc17a1 U28504 membrane channels and
transporters
1.47 3.33 3.6* 0.00049
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84 solute carrier family 25 (mitochondrial
adenine nucleotide translocator)
member 4
Slc25a4 D12770 metabolism 1.73 1.3 1.53*
84 syndecan 2 Sdc2 M81687 0.59 0.45 0.66* 0.00044
84 testis-specific heat shock protein-
related gene hst70
Hspa2 X15705 stress response proteins 0.45 0.55 0.52* 0.00047
84 thioredoxin reductase 1 Txnrd1 AF220760 1.15 2.3 3.88* 0.00043
84 thymosin, beta 10 Tmsb10 M17698 1.05 1.12 4.79* 0.00073
84 thyroid hormone receptor alpha Thra X12744,M31177 oncogenes and tumor
suppressors
0.61 0.62 0.75* 0.00039
84 tyrosine 3-monooxgenase/tryptophan
5-monooxgenase activation protein,
gamma polypeptide
Ywhag S55305 metabolism 1.02 1.35 2.04*
84 Tyrosine 3-monooxygenase
5-monooxygenase activation protein,
eta polypeptide
Ywhah D17445 metabolism 0.53 0.92 1.54*
84 Tyrosine 3-monooxygenase
5-monooxygenase activation protein,
zeta polypeptide
Ywhaz D17615 metabolism 0.51 0.71 1.66*
84 tyrosine aminotransferase Tat M18340 metabolism 0.7 0.46 0.2* 0.00042
84 urate oxidase Uox J03959 metabolism 1.66 0.86 0.36*
84 zinc finger protein 354A Znf354a M96548 transcription 0.52 0.37 0.22* 0.00048
Full list of differential genes classified according to Venn diagram (Figure 2).
*Ratios are statistically different compared with NL (P V .05).
Table W2. Functional Classificafion of the 290 Differential Genes.
Functional Classification Number
of Genes
% of Genes
apoptosis associated proteins 3 1.0
cell adhesion receptors/proteins 2 0.7
cell cycle 2 0.7
cell receptors 31 10.7
cell signaling, extracellular communication
proteins
9 3.1
cytoskeleton/motility proteins 4 1.4
DNA binding and chromatin proteins 2 0.7
DNA synthesis, recombination, and repair 4 1.4
extracellular matrix proteins 1 0.3
extracellular transport/carrier proteins 4 1.4
immune system proteins 2 0.7
intracellular transducers/effectors/modulators 30 10.3
membrane channels and transporters 8 2.8
metabolism 80 27.6
oncogenes and tumor suppressors 6 2.1
post-translational modification/protein folding 6 2.1
protein turnover 17 5.9
RNA processing, turnover, and transport 2 0.7
stress response proteins 18 6.2
trafficking/targeting proteins 6 2.1
transcription 15 5.2
translation 7 2.4
unclassified 31 10.7
290 100
